Dopamine has long been hypothesised to be involved in the pathogenesis of schizophrenia. The dopamine D2 receptor is a major site of action of neuroleptic agents used in the treatment of schizophrenia. Arinami et al. [1997; Human Mol Genet 6:577-582] have recently sequenced the dopamine receptor 2 (DRD2) gene in Japanese individuals and identified a novel polymorphism: a single cytosine deletion at position -141 disrupting a BstN1 restriction site with a frequency of 0.22 in their control group. They then found a strong association with this polymorphism and schizophrenia (p < 0.001) with an odds ratio of 0.60 in a Japanese population. We have attempted to verify their results by repeating the RFLP analysis on a sample of Scottish schizophrenics and controls. We then combined our data with those from another British sample recruited using similar procedures. The total combined sample size was 439 schizophrenics and 437 controls, We obtained a significant association-p = 0.02 with an odds ratio of 1.41. Schizophrenia is associated with the C insertion in the Japanese, but that association is reversed in Caucasians, Linkage disequilibrium with a causative polymorphism nearby is the most likely explanation for this reverse association. Am. J. Med. Genet, (Neuropsychiatr, Genet.) 88:407-410, 1999, (C) 1999 Wiley-Liss, Inc.
|Number of pages||4|
|Journal||American Journal of Medical Genetics|
|Publication status||Published - 1999|
- DRD2 gene
- linkage disequilibrium
- MOLECULAR VARIANT